TearClear
PrivateLast Round
Series C
Jun 28, 2023
Total Funding Raised
$51.95M
Company Overview
TearClear operates in Healthcare & Life Sciences and is based in Newport Beach, California. Its latest recorded funding round was a Series C round in June 2023.
TearClear is a life sciences company that develops ophthalmic drugs intended to transform trusted ophthalmic medications into preservative-free therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TearClear Comparables
Compare TearClear with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Laboratoires Théa | 74% | |
| Novartis | 72% | |
| Nemera | 71% |
For institutional investors. Book with your work email.
TearClear Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 28, 2023 | ||||
| Debt | Aug 2, 2022 | ||||
| Series B | Aug 11, 2020 | ||||
| Debt | Jan 31, 2020 | ||||
| Series A Extension | Feb 1, 2019 | ||||
Series A | May 30, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TearClear Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kohlberg Kravis Roberts | Series B |
| Flying L Partners | Series B |
| Falcon Vision | Series B |
| KKR | Series B |
| Visionary Ventures | Series B, Series A Extension, Series A |
| Bluestem Capital | Series B, Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 30, 2017
$4.5M round led by Bluestem Capital and Visionary Ventures.
For institutional investors. Book with your work email.
TearClear Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TearClear's valuation, stock price, and market status.
Is TearClear a public or private company?
TearClear is a private company.
What is the current stock price of TearClear?
TearClear is a private company, so its shares have no public market price. Caplight tracks TearClear's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TearClear worth (valuation)?
Valuation information for TearClear is not publicly available.
Can I buy TearClear stock?
TearClear shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TearClear's last funding round?
TearClear's most recent funding round was Series C on June 28, 2023.
Who are the main investors in TearClear?
Key investors in TearClear include Kohlberg Kravis Roberts, Falcon Vision, Visionary Ventures, Bluestem Capital.
Will TearClear IPO soon?
No public IPO plans have been announced for TearClear.
How can I track TearClear secondary market activity?
Caplight tracks bids, offers, and trades in TearClear's shares on secondary markets.